Denoclast (Denosumab) Injection

Description

Description

This page contains brief details about the drug denosumab, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Date of Approval

The U.S. FDA approved Denosumab for the first time on June 1, 2010, to treat postmenopausal women with osteoporosis at high risk for fracture.

Mechanism of Action of Denosumab

Osteoclast breaks the tissues in the bones and releases calcium into the blood. This process is called bone resorption. Denosumab acts by inhibiting osteoclast formation, thereby decreasing bone resorption and increasing bone mass and strength.

Uses of Denosumab

Osteoporosis in women postmenopause who are at high risk of fracture

Men with osteoporosis who are at increased risk of fracture

Bone loss in men due to reduced levels of testosterone caused as a result of prostate cancer surgery or treatment with medications

Osteoporosis in patients with a high risk of fracture due to long-term treatment with glucocorticoids.

And increase bone mass in women at high risk of fracture due to adjuvant aromatase inhibitor therapy for breast cancer.

Denosumab Dosage available

Denosumab is to be administered by a healthcare provider. It is injected subcutaneously under the skin of stomach, upper thigh or upper arm. Denosumab is to be given once every six months.